Table 2.
Characteristics of stage III colon cancer patients treated with adjuvant chemotherapy, by cohort*
| Characteristic | Efficacy | Effectiveness |
||||
| ACCENT, N = 8292 | SEER–Medicare, N = 2458 | CanCORS, N = 272 | NYSCR–Medicaid, <65 y†, N = 290 | NYSCR–Medicare, ≥65 y†, N = 446 | NCCN, N = 594 | |
| Non-oxaliplatin, n (%) | 6812 (82) | 1013(41) | 125 (46) | 224 (77) | 218 (49) | 33 (6) |
| Oxaliplatin, n (%) | 1480 (18) | 1445(59) | 147 (54) | 66 (23) | 228 (51) | 561 (94) |
| Age, y | ||||||
| Median years (range) | 60 (17–74) | 69(27–74) | ‡ | 54 (25–64) | 69 (65–74) | 56 (19–74) |
| <50 | 1589 (19) | 47(2) | 37 (14) | 101 (35) | — | 171 (29) |
| 50–64 | 3943 (48) | 252(10) | 138 (51) | 189 (65) | — | 281 (47) |
| 65–69 | 1581 (19) | 1136(46) | 51 (19) | — | 225 (50) | 80 (13) |
| 70–74 | 1179 (14) | 1023(42) | 46 (17) | — | 221 (50) | 62 (10) |
| Sex, n (%) | ||||||
| Women | 3751 (45) | 1279(52) | 97 (36) | 139 (48) | 237 (53) | 311 (52) |
| Men | 4541 (55) | 1179(48) | 175 (64) | 151 (52) | 209 (47) | 283 (48) |
| Race, n (%)§ | ||||||
| White | 3697 (90) | 1992(81) | 191 (70) | 165 (57) | 364 (82) | 456 (77) |
| Black | 201 (5) | 275(11) | 47 (17) | 90 (31) | 59 (13) | 71 (12) |
| Asian | 90 (2) | 76(3) | 12 (4) | 31 (11) | 19 (4) | 48 (8) |
| Other | 114 (3) | 115(5) | 22 (8) | ‖ | ‖ | 19 (3) |
| Latino | ||||||
| Yes | NA | 155(6) | 26 (10) | 74 (26) | 26 (6) | 38 (6) |
| No | — | 2303(94) | 246 (90) | 216 (74) | 420 (94) | 512 (86) |
| Unknown | — | — | 44 (7) | |||
| CCI, n (%)¶ | ||||||
| 0 | NA | 2065(84) | NA | 199 (69) | 336 (75) | 447 (75) |
| 1 | — | 245(10) | — | 41 (14) | 67 (15) | 87 (15) |
| ≥2 | — | 148(6) | — | 28 (10) | 43 (10) | 60 (10) |
| Unknown | — | — | 22 (8) | — | ||
| ACE-27, n (%) | ||||||
| None | NA | NA | 89 (33) | NA | NA | NA |
| Mild | — | — | 104 (38) | — | — | — |
| Moderate | — | — | 43 (16) | — | — | — |
| Severe | — | — | 36 (13) | — | — | — |
| Performance status, n (%) | ||||||
| 0 | 3373 (82) | NA | NA | NA | NA | NA |
| 1 | 711 (17) | — | — | — | — | — |
| 2 | 14 (<1) | — | — | — | — | — |
| Marital status, n (%) | ||||||
| Married | NA | 1487(60) | 188 (69) | 101 (35) | 249 (56) | NA |
| Single | — | 274(11) | 27 (10) | 127 (44) | 66 (15) | — |
| Widowed/divorced | — | 606(25) | 54 (20) | 59 (20) | 120 (27) | — |
| Other | — | 91(4) | ‖ | ‖ | ‖ | — |
| AJCC stage, n (%) | ||||||
| IIIA | 772 (9) | 320(13) | 35 (13) | 20 (7) | 54 (12) | 73 (12) |
| IIIB | 4687 (57) | 1330(54) | 136 (50) | 169 (58) | 232 (52) | 306 (52) |
| IIIC | 2820 (34) | 806(33) | 87 (32) | 100 (34) | 160 (36) | 212 (36) |
| III NOS | 13 (<1) | ‖ | 14 (5) | ‖ | ‖ | |
| Differentiation, n (%) | ||||||
| Well/Moderate | NA | 1705(69) | 199 (73) | 196 (68) | 293 (66) | 412 (69) |
| Un/Poor | — | 686(28) | 67 (25) | 85 (29) | 139 (31) | 156 (26) |
| Unknown | — | 67(3) | ‖ | ‖ | 14 (3) | 26 (4) |
| Median income, US dollars# | ||||||
| Top quantile | NA | $185 394 | — | $106 973 | $134 325 | $153 918 |
| Third quantile | — | $52 828 | 83 (31%) | $47 266 | $61 986 | $65 367 |
| Second quantile | — | $40 203 | 43 (16%) | $35 637 | $43 636 | $49 958 |
| First quantile | — | $29 922 | 45 (17%) | $24 167 | $34 663 | $36 315 |
| Bottom quantile | — | $8,366 | 49 (18%) | $14 ,271 | $14 271 | $14 642 |
| Missing | — | 52 (19%) | — | |||
| Diagnosis year, n (%) | ||||||
| 1998 | 20 (<1) | — | — | — | — | — |
| 1999 | 1195 (14) | — | — | — | — | — |
| 2000 | 2854 (34) | — | — | — | — | — |
| 2001 | 3034 (37) | — | — | — | — | — |
| 2002 | 1189 (14) | — | — | — | — | — |
| 2003 | — | — | — | — | — | — |
| 2004 | — | 690(28) | 220 (81) | 97 (33) | 163 (37) | — |
| 2005 | — | 612(25) | 52 (19) | 100 (34) | 161 (36) | 72 (12) |
| 2006 | — | 576(23) | — | 93 (32) | 122 (27) | 143 (24) |
| 2007 | — | 580(24) | — | — | — | 133 (22) |
| 2008 | — | — | — | — | — | 159 (26) |
| 2009 | — | — | — | — | — | 87 (15) |
| Median time from surgery to first chemo, d (range) | NA | 44 (0–120) | 43 (0–115) | 39 (0–118) | 47 (9–120) | 46 (20–116) |
| Median FU time, d (range) | ** | 1218 (14–2157) | 1479 (90–2305) | 773 (35–1418) | 782 (1–1418) | 608 (120–1588) |
ACCENT = Adjuvant Colon Cancer End Points Group; ACE-27 = Adult Comorbidity Evaluation-27; AJCC = American Joint Committee on Cancer; CCI = Charlson Comorbidity Index; CanCORS = Cancer Care Outcomes Research & Surveillance Consortium; N = Node; NA = not available; NCCN = National Comprehensive Cancer Network Outcomes Database; NYSCR–Medicaid = New York State Cancer Registry linked to Medicaid claims; NYSCR–Medicare = New York State Cancer Registry linked to Medicare claims; SEER–Medicare = Surveillance Epidemiology and End Results registry linked to Medicare claims; T = Tumor.
Patients included in the column titled “NYSCR–Medicaid <65 y, N = 290” are all patients less than 65 years of age who have continuous Medicaid enrollment for 6 months from diagnosis. Thirty-two percent of the patients included here are less than 65 years of age with enrollment in Medicaid and Medicare. Patients included in the column titled “NYSCR–Medicare ≥65 y, N = 446” are all patients 65 years of age and older that have continuous Medicare enrollment for 6 months from diagnosis. Twenty-eight percent of the patients included here are 65 years of age or older with enrollment in Medicare and Medicaid.
Only categorical data for age are available for CanCORS, and no median can be reported.
Race and ethnicity: In NYSCR, Asian patients are included with “other” because of small numbers. Latino ethnicity is not separately available in ACCENT.
Comorbidity: CanCORS reports comorbidity using the ACE-27, NCCN, the CCI, NYSCR, the Deyo modification of the CCI, and SEER–Medicare, Deyo-Klabunde modification of the CCI. ACCENT contains performance status only which was imputed for 4246 patients using multiple imputation based on age, sex, race, treatment, and substage.
N < 11. Value omitted to ensure patient confidentiality.
Income was measured categorically in CanCORS: >$60 000; $40 000–$60 000; $20 000–$40 000; <$20 000.
Median follow-up for all studies was greater than 5 years.